A phase 2 a, randomized open label study to evaluate the efficacy, safety tolerability, pharmocokinetics and pharmacodynamics of ISIS 702843 Administered subcutaneously to patients with non-transfusion depenmdent B- thalassemia intermedia


Karakaş Z. (Executive), Tanyıldız H. G.

Other International Funding Programs, 2021 - 2023

  • Project Type: Other International Funding Programs
  • Begin Date: April 2021
  • End Date: April 2023